Binod Dhakal, MD

Articles

Talquetamab: Efficacy, AE Management, and Outpatient Strategies and Insights From ASCO 2025

August 1st 2025

Panelists discuss how extended follow-up from the MonumenTAL-1 trial confirms the durable efficacy and favorable infection profile of talquetamab, while ongoing trials like TALISMAN aim to mitigate its unique toxicity profile.

Insights Into CAR T Therapy in Earlier vs Later Lines

August 1st 2025

Panelists discuss how the CARTITUDE-4 data support early use of ide-cel in triple class–exposed myeloma patients, emphasizing the importance of avoiding attrition by not delaying highly effective therapies.

CARTITUDE-4 Subgroup Analysis: When Cilta-Cel Should Be Considered

July 25th 2025

Panelists discuss how subgroup analyses of cilta-cel support its efficacy in high-risk cytogenetics and extramedullary disease, though bridging therapy and patient selection remain key for optimal outcomes.

Positioning ADCs and CAR T in R/R Multiple Myeloma

July 25th 2025

Panelists discuss how sequencing CAR T-cell therapy, bispecifics, and antibody-drug conjugates (ADCs) will become increasingly complex, with treatment decisions depending on patient characteristics, accessibility, and toxicity profiles.

ASCO Insights: Experts Discuss Recent DREAMM-7 and DREAMM-8 Data

July 18th 2025

Panelists discuss how updated data from the DREAMM-7 and DREAMM-8 studies validate the early integration of BCMA-targeted therapies like belantamab mafodotin, showing promising efficacy and manageable ocular toxicities.

ASCO 2025 Insights: CARTITUDE-1–– Long-Term Follow-Up

July 18th 2025

Panelists discuss how 5-year follow-up data from the CARTITUDE-1 trial demonstrate durable responses and potential functional cures in a subset of relapsed/refractory myeloma patients treated with cilta-cel.

Navigating the Current Landscape of Relapsed/Refractory Multiple Myeloma

July 11th 2025

Panelists discuss how the evolving treatment landscape, including CAR T-cell therapy and bispecifics, has made it possible to offer cellular therapies like cilta-cel as early as second-line treatment for eligible patients.

Real-World Decision-Making: Triplet vs Quadruplet in NDMM-TI

July 11th 2025

Panelists discuss how novel agents like iberdomide show promising efficacy and manageable toxicity in early-phase studies for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Emerging Data in Transplant-Ineligible NDMM: DREAMM-10, ENDURANCE, and CC-220-MM-001

July 4th 2025

Panelists discuss how novel agents like iberdomide show promising efficacy and manageable toxicity in early-phase studies for transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

Targeted Insights: IMROZ Trial and the Role of 1q21+  and MRD/PET-CT

July 4th 2025

Panelists discuss how isatuximab-containing quadruplet regimens offer clinical benefit in patients with 1q gain or amplification, though its advantage appears to reflect a class effect among CD38-targeting agents.

CEPHEUS Subgroup Analyses: Insights From ASCO 2025

June 27th 2025

Panelists analyses from the CEPHEUS suggest that quadruplet regimens provide broad benefits in transplant-ineligible patients, though ultra–high-risk subtypes may require novel strategies discuss how subgroup.

Management Approaches and Unmet Needs in Transplant-Ineligible NDMM

June 27th 2025

Panelists discuss how treating newly diagnosed, transplant-ineligible multiple myeloma patients requires a nuanced approach that accounts for comorbidities, age, and functional status to optimize induction therapy.

ASCO 2025: Updates From PERSEUS, ADVANCE, and Other Trials in Transplant-Eligible NDMM

June 20th 2025

Panelists discuss how data from the PERSEUS trial supports the use of daratumumab in quadruplet regimens to improve sustained minimal residual disease negativity and progression-free survival in transplant-eligible myeloma patients.

Managing Transplant-Eligible NDMM: Current Treatments

June 20th 2025

Panelists discuss how quadruplet-based induction therapy, including anti-CD38 monoclonal antibodies, is becoming the preferred frontline treatment for transplant-eligible patients with multiple myeloma based on risk stratification.

How to Optimize Patient Selection for Multiple Myeloma Therapies: With Binod Dhakal, MD; and Muhamed Baljevic, MD

December 6th 2024

Drs Dhakal and Baljevic discuss first- and subsequent-line treatment options for patients with multiple myeloma.

Dr Dhakal on Notable Multiple Myeloma Trials Presented in 2024

October 29th 2024

Binod Dhakal, MD, discusses key trials presented at the 21st International Myeloma Society Annual Meeting in patients with multiple myeloma.

Dr Dhakal on the Design of the CARTITUDE-4 Study in R/R Myeloma

October 23rd 2024

Binod Dhakal, MD, discusses the design of the CARTITUDE-4 study investigating cilta-cel in relapsed/refractory multiple myeloma.

Dr Dhakal on Survival and Safety Outcomes With Cilta-Cel in R/R Myeloma

October 2nd 2024

Binod Dhakal, MD, discusses survival data with ciltacabtagene autoleucel in lenalidomide-refractory relapsed/refractory multiple myeloma.

Dr. Dhakal on the Mechanism of Action of Orva-Cel in Multiple Myeloma

February 26th 2021

Binod Dhakal, MD, discusses the mechanism of action of orvacabtagene autoleucel in multiple myeloma.

Dr. Dhakal on Responses Achieved With Orva-Cel in Multiple Myeloma

February 16th 2021

Binod Dhakal, MD, discusses responses achieved with orvacabtagene autoleucel in patients with multiple myeloma.

NEXT PAGE
PREVIOUS PAGE